TABLE 1

Patient Characteristics

PatientSexAge (y)Tumor classificationPre-177Lu-DOTATATE therapy177Lu-DOTATATE therapy
Prior therapyTg (μg/mL)*TSH (mU/L)131I/123I scan111In-octreotide§PDCumulative dose (GBq)No. of treatments
1M52PTCTT, ND, RIT (16.7 GBq), R49.10.1682Yes25.78
2F73FTCTT, RIT (10.6 GBq), R, C5665<0.012Yes22.43
3F52HCTCTT, ND, RIT (1.9 GBq)11100.023Yes27.48
4F74HCTCTT, RIT (12.9 GBq)126NA+2No30.14
5F52HCTCTT, RIT (13.0 GBq), R2370.24±1No22.73
  • * Serum Tg level during levothyroxine treatment before 177Lu-DOTATATE therapy.

  • TSH during levothyroxine treatment.

  • Outcomes of radioiodine scan. + = positive; − = negative; ± = mixed.

  • § Tumor uptake score on 111In-octreotide scintigraphy. 1 = uptake in lesion < uptake in liver; 2 = uptake in lesion = uptake in liver; 3 = uptake in lesion > uptake in liver (as described in [19]).

  • Documented PD within 1 y before therapy.

  • RIT, 131I therapy (cumulative dose).

  • TT = total thyroidectomy; ND = neck dissection; R = external radiation; C = chemotherapy; NA = not available.